SGK1 and chronic kidney disease: By demonstrating an EMPA-mediated inhibition of IL-1β-induced SGK1 expression, this effect might be a potential explanation for the positive clinical effect seen with the use of SGLT2i in CKD patients irrespective of the presence and absence of diabetes.